Text Size

A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors

This study is currently recruiting participants.
Verified May 2013 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01626209
First received: June 20, 2012
Last updated: May 10, 2013
Last verified: May 2013
History of Changes

June 20, 2012
May 10, 2013
July 2012
December 2013   (final data collection date for primary outcome measure)
Dose Limiting Toxicity (DLT) [ Time Frame: During Cycle 1 (28 days) ] [ Designated as safety issue: Yes ]
An adaptive Bayesian logistic regression model (BLRM) for dose escalation with overdose control will guide the dose escalation. The recommended dose is the one with the highest posterior probablity of DLT in the target interval(16%,33%) among the doses fulfilling the overdose criterion that there is less than 25 % chance of excessive toxicity. A clinical synthesis of the available toxicity information including adverse event that are not DLTs, Pharmacokinetics, Pharmacodynamics, efficacy as well as the recommnendations from the BLRM will be used to determine the dose.
Same as current
Complete list of historical versions of study NCT01626209 on ClinicalTrials.gov Archive Site
  • Type, frequency and severity of of Adverse Events (AEs) (based on CTCAE version 4.03 [ Time Frame: On a continous basis up to when patient discontinues for progression or until any discontinuation criteria are met e.g AE, patient withdraws consent, Investigator decision; up to 30 days post last study dose ] [ Designated as safety issue: Yes ]
  • Laboratory and vital sign parameters [ Time Frame: Every week cycle 1 & 2 then monthly up to when patient discontinues for progression or until any discontinuation criteria are met e.g AE, patient withdraws consent, Investigator decision, ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for Cmax [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for Tmax [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for AUCtlast [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for AUCtau [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for AUCinf [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for AUC%Extrap [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for CL/F [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for Racc [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for T1/2acc [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for Vss/F [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: No ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for Rsqadj [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: No ]
  • Pharmacokinetics: plasma concentration-time profiles of BKM120 for other PK parameters [ Time Frame: Day 1 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) Day 8 (predose, postdose : 0.5,1,1.5,2,3,4,6,8,24 hr) and Day 28 (predose, postdose: 0.5,1,1.5,2,3,4,6,8,24 hr) ] [ Designated as safety issue: No ]
  • Objective Response Rate (ORR) [ Time Frame: Every 8 weeks up to when patient discontinues for progression or until any other discontinuation criteria are met e.g AE, patient withdraws consent, Investigator decision ] [ Designated as safety issue: No ]
    Evaluated with CT/MRI according to RECIST criteria (RECIST guidelines version 1.1)
  • Time to Progression (TTP) [ Time Frame: Every 8 weeks up to when patient discontinues for progression or until any other discontinuation criteria are met e.g AE, patient withdraws consent, Investigator decision ] [ Designated as safety issue: No ]
    Evaluated with CT/MRI according to RECIST criteria (RECIST guidelines version 1.1)
Same as current
Not Provided
Not Provided
 
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
A Phase I Study of BKM120, Administered Orally in Adult Chinese Patients With Advanced Solid Tumors

Dose escalation study with a dose expansion phase, to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of two dose levels of BKM120 when administered orally.

This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology
Drug: BKM120
This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
Experimental: BKM120 at: 80 and 100mg/day dose levels
Intervention: Drug: BKM120
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with histologically-confirmed, advanced unresectable breast cancer or advanced carcinoma with squamous cell histology (including NSCLC, SCCHN, and esophageal) who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
  • Patient must provide a representative archival or fresh tumor biopsy for shipping to a Novartis designated laboratory for profiling. Note: one block or ≥ 15 unstained slides is required to determine the PI3K activation status. Whenever possible ≥ 20 unstained slides is preferred.
  • Patient has measurable and/or non-measurable disease as per RECIST v1.1 guidelines for solid tumors
  • Patient is an adult (female or male) ≥ 18 years of age on the day of consent signature
  • Patient has an Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2

Exclusion Criteria:

  • Patient has received previous treatment with a PI3K inhibitor
  • Patient has symptomatic CNS metastases
  • Patients with asymptomatic CNS metastases may participate in this trial. The patient must have completed any prior local treatment for CNS metastases ≥ 14 days prior to the start of study treatment (including radiotherapy and/or surgery). If the patient is receiving ongoing corticosteroid therapy, the following criteria must be met:
  • The patient must be receiving a stable or decreasing dose ≤ dexamethasone 4 mg/day or equivalent anti-inflammatory potency of another corticosteroid
  • The dose of corticosteroid may not have been escalated for at least 14 days before the start of study treatment
  • Patient is currently receiving increasing or chronic treatment with corticosteroids (>dexamethasone 4 mg or equivalent anti-inflammatory potency of another corticosteroid) or another immunosuppressive agent.
  • Note: Topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular) are allowed. Patients with previously treated and asymptomatic brain metastases, are permitted to use corticosteroids as per specific protocol criteria

  • Patient is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzyme CYP3A. The patient must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the treatment is initiated. Switching to a different medication prior to starting study treatment is allowed.

    • Other protocol-defined inclusion/exclusion criteria may apply.
Both
18 Years and older
No
Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals
China
 
NCT01626209
CBKM120Z2102
Yes
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP